{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:00:56Z","timestamp":1775782856286,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021735","name":"CRIG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Flanders Inter-University Institute for Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118656","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:45:19Z","timestamp":1761266719000},"page":"118656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modeling of glucocorticoid resistance in multiple myeloma reveals mechanisms and markers of glucocorticoid resistance"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-0314","authenticated-orcid":false,"given":"Bert","family":"Luyckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Derollez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Staessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Verhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Fijalkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter Van","family":"Vlierberghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorien","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-9718","authenticated-orcid":false,"given":"Karolien","family":"De Bosscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118656_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118656_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118656_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118656_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118656_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2025.118656_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118656_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance\u2013changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2025.118656_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1172\/JCI88886","article-title":"Glucocorticoid receptors: finding the middle ground","volume":"127","author":"Desmet","year":"2017","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118656_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188430","article-title":"Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies","volume":"1874","author":"Clarisse","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118656_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","article-title":"Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes","volume":"182","author":"Smith","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.biopha.2025.118656_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-013-1477-8","article-title":"Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis","volume":"63","author":"Kfir-Erenfeld","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.118656_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.20050433","article-title":"Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis","volume":"203","author":"Sionov","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118656_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib15","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/sj.cdd.4401456","article-title":"Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance","volume":"11","author":"Schmidt","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2025.118656_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000342502","article-title":"Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance","volume":"24","author":"Ramamoorthy","year":"2013","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.biopha.2025.118656_bib17","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1158\/1535-7163.MCT-06-0344","article-title":"Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells","volume":"5","author":"S\u00e1nchez-Vega","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118656_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.V79.1.213.213","article-title":"A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA","volume":"79","author":"Moalli","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","article-title":"Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia","volume":"24","author":"Piovan","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118656_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/me.2009-0466","article-title":"Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis","volume":"24","author":"Spokoini","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118656_bib21","doi-asserted-by":"crossref","first-page":"26922","DOI":"10.18632\/oncotarget.4616","article-title":"Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma","volume":"6","author":"Kervo\u00eblen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118656_bib22","first-page":"26","article-title":"CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy","volume":"1","author":"Luyckx","year":"2024","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2025.118656_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48818-9","article-title":"Glucocorticoids paradoxically promote steroid resistance in b cell acute lymphoblastic leukemia through CXCR4\/PLC signaling","volume":"15","author":"Abdoul-Azize","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118656_bib24","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118656_bib25","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-\u03baB (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118656_bib26","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.97.8.3919","article-title":"Glucocorticoids repress NF-\u03baB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell","volume":"97","author":"De Bosscher","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118656_bib27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2141.2008.07549.x","article-title":"Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1)","volume":"144","author":"S\u00e1nchez-Vega","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2025.118656_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.biopha.2025.118656_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118656_bib30","article-title":"Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma","author":"Malyutina","year":"2024","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2025.118656_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107709","article-title":"CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy","author":"Luyckx","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2025.118656_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-023-04900-x","article-title":"Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells","volume":"80","author":"Clarisse","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2025.118656_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1007","article-title":"Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance","volume":"7","author":"Nikesitch","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.biopha.2025.118656_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","article-title":"Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation","volume":"102","author":"Tarte","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118656_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107469","article-title":"Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines","volume":"139","author":"Zeissig","year":"2024","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2025.118656_bib37","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1002\/jcp.26245","article-title":"The MIP-1\u03b1 autocrine loop contributes to decreased sensitivity to anticancer drugs","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2025.118656_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.584232","article-title":"HS-5 and HS-27A stromal cell lines to study bone marrow mesenchymal stromal Cell-Mediated support to cancer development","volume":"8","author":"Adamo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118656_bib39","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/1538-7445.AM2022-3023","article-title":"Fatty acid synthase (FASN) inhibitors synergize with carfilzomib (CFZ) in acute myeloid leukemia (AML) and multiple myeloma (MM)","volume":"82","author":"Peng","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118656_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118656_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","article-title":"Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance","volume":"124","author":"Ge","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118656_bib42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/blood.V87.1.314.bloodjournal871314","article-title":"Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites","volume":"87","author":"Chen","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib43","first-page":"1","article-title":"Exploring the impact of dexamethasone on gene regulation in myeloma cells","volume":"6","author":"Gaborit","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.biopha.2025.118656_bib44","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-05-0523","article-title":"The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype","volume":"11","author":"Yaccoby","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118656_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2023.1155621","article-title":"Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment","volume":"13","author":"Matamala Montoya","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118656_bib46","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/sj.bjc.6605072","article-title":"Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism","volume":"100","author":"Beesley","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118656_bib47","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.207704","article-title":"A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis","volume":"104","author":"Besse","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2025.118656_bib48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1878-0261.13582","article-title":"Fatty acid synthase (FASN) signalome: a molecular guide for precision oncology","volume":"18","author":"Menendez","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2025.118656_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046484","article-title":"Inhibition of fatty acid metabolism reduces human myeloma cells proliferation","volume":"7","author":"Tirado-V\u00e9lez","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.biopha.2025.118656_bib50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2011-10-384784","article-title":"CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease","volume":"120","author":"Dairaghi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib51","first-page":"316","article-title":"Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2025.118656_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2022.846310","article-title":"Targeting chemokine receptor CCR1 as a potential therapeutic approach for multiple myeloma","volume":"13","author":"Gilchrist","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118656_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","article-title":"Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes","volume":"182","author":"Smith","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.biopha.2025.118656_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112888","article-title":"Glucocorticoid resistance in IKZF1-Deleted BCP-ALL: it is PTEN again","volume":"132","author":"Van Der Meer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118656_bib55","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1128\/MCB.05866-11","article-title":"Ligand-Independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling","volume":"31","author":"Galliher-Beckley","year":"2011","journal-title":"Mol. Cell. Biol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:42:48Z","timestamp":1775781768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":55,"alternative-id":["S0753332225008509"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118656","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling of glucocorticoid resistance in multiple myeloma reveals mechanisms and markers of glucocorticoid resistance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118656"}}